Results 181 to 190 of about 112,735 (309)

Myocardial Perfusion Defects in Hypertrophic Cardiomyopathy Mutation Carriers

Journal of the American Heart Association, EarlyView., 2021
Background Impaired myocardial blood flow (MBF) in the absence of epicardial coronary disease is a feature of hypertrophic cardiomyopathy (HCM). Although most evident in hypertrophied or scarred segments, reduced MBF can occur in apparently normal segments.
Rebecca K. Hughes, Claudia Camaioni, João B. Augusto, Kristopher Knott, Ellie Quinn, Gabriella Captur, Andreas Seraphim, George Joy, Petros Syrris, Perry M. Elliott, Saidi Mohiddin, Peter Kellman, Hui Xue, Luis R. Lopes, James C. Moon   +14 more
wiley   +1 more source

High sensitive troponin T elevation in an oncology patient on treatment with Pembrolizumab. [PDF]

Adv Lab Med
Alcalde Morales A, Reyes Milla M, Mondéjar García R, León Justel A.   +3 more
europepmc   +1 more source

Cardiac surveillance in immune checkpoint inhibitor therapy: Insights from the Essen Cardio‐oncology Registry

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia, Lisa Zimmer, Lena Lampe, Dimitra Vlachopoulou, Matthias Totzeck, Tienush Rassaf, Raluca I. Mincu   +6 more
wiley   +1 more source

Effect of hemodialysis on high-sensitivity cardiac troponin T levels in patients with hypervolemia. [PDF]

Front Nephrol
Tinawi M, Bastani B.
europepmc   +1 more source

Reversal of evolving third‐degree atrioventricular block in utero by early detection and combination therapy

Ultrasound in Obstetrics &Gynecology, EarlyView.
S. Lertvutivivat, L Gotha, K. Papneja, N. Dutil, L. Stennett, L. T. Hiraki, L. Freud   +6 more
wiley   +1 more source

Neurokinin‐1 receptor activation protects against cardiac fibrosis, inflammation and diastolic dysfunction in type 2 diabetic mice

British Journal of Pharmacology, EarlyView.
Background and Purpose The pathogenesis of type 2 diabetes mellitus (T2DM)‐induced cardiomyopathy involves cardiac fibrosis that leads to diastolic dysfunction. We established that replacement of lost substance P (SP) that occurs in T2DM reduces cardiac fibrosis and decreases inflammation in T2DM mice and non‐human primates.
Alexander Widiapradja, Heather Connery, Brody J. Helmick, Kallie J. Schafner, Vamsi Manchikalapudi, Hannah Horvath, Sophia Gugino, Tamas Kriska, Anja Herrnreiter, Evan DeVallance, William B. Campbell, Scott P. Levick   +11 more
wiley   +1 more source

Long Troponin T to Separate Troponin Elevations Among Patients With Atrial Fibrillation Versus Myocardial Infarction. [PDF]

J Am Heart Assoc
Airaksinen KEJ, Teppo K, Vasankari T, Paana T, Junes H, Salonen S, Tuominen T, Simonen S, Strandberg M, Hellman T, Linko-Parvinen A, Pallari HM, Jaakkola S, Wittfooth S.   +13 more
europepmc   +1 more source

A comprehensive review of cancer‐induced cardiac wasting

British Journal of Pharmacology, EarlyView.
Cancer is frequently accompanied by cachexia, a systemic syndrome characterized by progressive loss of skeletal muscle mass, with or without loss of fat mass. Increasing evidence indicates that cancer can also induce cardiac muscle wasting, which is associated with structural cardiac remodelling, impaired contractile function and the development of ...
Alessia Lena, Muhammad Shahzeb Khan, Ulrich Keller, Lars Bullinger, Dominik P. Modest, Markus S. Anker   +5 more
wiley   +1 more source

Troponin T/I discordance in immune checkpoint inhibitor myositis in a patient with ischaemic cardiac disease: a case report. [PDF]

Eur Heart J Case Rep
El-Hisnawi A, D'Ancona G, Heinze H, Steinicke R, Ince H.   +4 more
europepmc   +1 more source

Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes, Florian Buehning, Tobias Lerchner, Julia Vogel, Raluca I. Mincu, Matthias Totzeck, Tienush Rassaf, Lars Michel   +7 more
wiley   +1 more source